ArticleEmerging infectious diseases2015
Prevalence of hepatitis E virus antibodies, Israel, 2009-2010.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Seroprevalence of Hepatitis E Virus Infection in Middle Eastern Countries: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Meta-Analysis of Human IgG anti-HEV Seroprevalence in Industrialized Countries and a Review of Literature.Viruses · 2019Pooled it
- Systematic review and meta-analysis of the seroprevalence of hepatitis E virus in the general population across non-endemic countries.PloS one · 2019Pooled it
- Dimethyl Fumarate-Associated Acute Hepatocellular Injury Assessed for Causality Using the Updated RUCAM: A Biopsy-Supported Case Report.Clinical case reports · 2026Article
- Article
- Hepatitis E virus (HEV) infection among the Arab population in Northern Israel: an insight into the seroepidemiology and associated risk factors.Epidemiology and infection · 2025Article
- Development and Application of a Nanobody-Based Competitive ELISA for Detecting Antibodies against Hepatitis E Virus from Humans and Domestic Animals.Microbiology spectrum · 2023Article
- Identification of Hepatitis E Virus Genotypes 3 and 7 in Israel: A Public Health Concern?Viruses · 2021Article
- The Israel National Sera Bank: Methods, Representativeness, and Challenges.International journal of environmental research and public health · 2021Article
- Seroprevalence of hepatitis E virus in dromedary camels, Bedouins, Muslim Arabs and Jews in Israel, 2009-2017.Epidemiology and infection · 2019Article
- Hepatitis E in pigs in Israel: seroprevalence, molecular characterisation and potential impact on humans.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018Article
- Hepatitis E Virus Genotype 3 in Sewage and Genotype 1 in Acute Hepatitis Cases, Israel.The American journal of tropical medicine and hygiene · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated prevalence of hepatitis E virus in a sample of the population of Israel. The overall seroprevalence of antibodies to the virus was 10.6% (95% CI 8.4%-13.0%); age-adjusted prevalence was 7.6%. Seropositivity was associated with age, Arab ethnicity, low socioeconomic status, and birth in Africa, Asia, or the former Soviet Union.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.